When a country accounts for 60 per cent of the world’s vaccine production, the statistic is usually interpreted as an indication of manufacturing scale. But there is another way to look at it. This scale represents decades of scientific knowledge, development expertise, specialised infrastructure, regulatory experience, and an understanding of how vaccines move from laboratories to large-scale delivery.
That makes India’s position in global vaccines more than a manufacturing achievement, representing an ecosystem built around one of the most complex areas of healthcare. The question now is how far that ecosystem can extend upstream, towards the discovery and development of the next generation of vaccines.
This requires recongising that the manufacturing capabilities can create a strong foundation for scientific origination, while also creating the conditions for capital to participate much earlier in the value chain.
The advantage of an ecosystem built around vaccines
Vaccine discovery does not happen in isolation. It depends on a network of scientific research, clinical development, regulatory expertise, manufacturing capabilities, and an understanding of population-level healthcare needs. India’s experience across these areas gives it a distinctive base for exploring the next phase of vaccine innovation.
There are already indications of a broader shift in Indian life sciences. Over the past decade, the country has witnessed significant growth on many fronts, including its innovation pipeline, biotech ecosystem, and patent activity. Alongside this, Indian corporations and institutes have witnessed the emergence of novel therapeutic assets.
For vaccines specifically, this evolution is important because the distance between discovery and scale can be shorter when capabilities across the value chain exist within the same ecosystem. Scientific ideas can be developed with a clearer understanding of manufacturability, cost, access, and eventual deployment. These considerations are important for vaccines, where global impact depends as much on reach as scientific efficacy.
It also changes the economics of innovation. When research, development, manufacturing and distribution capabilities are closer together, companies can potentially move from scientific validation to commercial scale with fewer structural gaps. That can make the ecosystem more efficient at converting scientific opportunity into economic and societal value.
Moving further upstream
The next opportunity, therefore, may lie in moving further upstream without moving away from the strengths India has already developed.
Discovery requires a different investment horizon from manufacturing. Early scientific programs can take years to demonstrate proof of concept, Many will not progress to a market-ready product. This makes patient capital important, alongside investors and institutions that understand scientific risk and can support companies through long development cycles.
It also calls for a different approach to risk. Not every discovery program will lead to a successful vaccine. Early-stage investments come with inherent uncertainty and long timelines, making predictable short-term returns an unrealistic expectation. A stronger ecosystem is one where multiple scientific bets can be made, the strongest programmes can attract followon capital, and successful platforms can generate value beyond a single product.
Similarly, stronger connections between academic research and industry can help promising discoveries move beyond the laboratory, while shared infrastructure will enable early-stage companies to access capabilities that would otherwise be difficult to build independently. India has already begun developing such mechanisms through industry-academia programs, technology transfer networks, and research initiatives spanning the innovation lifecycle.
For vaccine discovery, these connections become especially valuable. The ability to understand a scientific problem, validate it clinically, develop the technology, and eventually manufacture at scale needs to function as a connected pathway rather than as separate capabilities. The stronger that pathway becomes, the more efficiently capital, talent, and scientific expertise can move through it.
Regulatory predictability will be equally important as India moves further upstream. For companies investing in novel vaccine platforms and early-stage discovery, the regulatory pathway needs to be sufficiently clear from the outset, with well-defined guidelines, predictable review processes, and reasonable timelines for approvals. The objective should not be to lower the regulatory bar, but to provide greater clarity on the path to meeting it. This is particularly important for emerging technologies, where uncertainty around applicable guidelines or prolonged processing timelines can add significant cost and delay to programmes that are already exposed to scientific risk.
A more predictable regulatory environment can also improve the ability of investors to underwrite early-stage innovation. When companies and investors have greater visibility on the evidence required, approval pathway and expected timelines, they can make better informed decisions on capital allocation and development milestones. Clear regulatory pathways can therefore become an important part of the innovation infrastructure—helping ensure that scientific breakthroughs are not held back by avoidable uncertainty between discovery, clinical development and eventual deployment.
From manufacturing strength to discovery potential
The most interesting question for India is not whether it can replicate established global models of pharmaceutical innovation. It is whether it can build on what is already distinctive about its own ecosystem.
India currently has over 10,000 pharmaceutical manufacturing facilities and more than 650 USFDA-compliant plants, the highest number outside the US. Its combination of scientific talent, development capabilities, cost efficiency, a large and diverse population, and established manufacturing depth creates the possibility of connecting discovery with scale for global relevance. That possibility should also be viewed with a long-term lens.
The emergence of a discovery ecosystem is unlikely to be defined by one breakthrough or one company. Its real measure will be whether scientific ideas originating in India can move through a consistent pathway from research to global deployment.
This is where the opportunity becomes larger than any individual vaccine. A mature discovery ecosystem can create intellectual property, technology platforms, specialised talent and companies capable of generating multiple innovations over time. The resulting value is not limited to the product that eventually reaches the market; it also lies in the capabilities and assets created along the journey. India’s vaccine manufacturing leadership has already demonstrated what becomes possible when scientific capability, entrepreneurship, infrastructure, and scale converge around a healthcare need. The next opportunity is to build further on that foundation by creating an environment where scientific risk can be taken earlier, capital can stay invested longer, and successful innovation can scale globally.
The aspiration, then, need not be to move from “made in India” to “discovered in India” as though one replaces the other. It is to make the two increasingly connected.
The larger opportunity is to build an ecosystem where India not only participates in the final stages of global vaccine value creation but increasingly captures value from the ideas, technologies, and companies that shape those products from the beginning.